How to Buy Kalvista Pharmaceuticals Stock
Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs.
Kalvista Pharmaceuticals stock last closed at $12.01, up 0.08% from the previous day, and has increased 4.98% in one year. It has overperformed other stocks in the Biotechnology industry by 0.83 percentage points. Kalvista Pharmaceuticals stock is currently +64.52% from its 52-week low of $7.30, and -22.52% from its 52-week high of $15.50.
As of Apr 21, 2025, there are 49.72M shares of KALV outstanding. The market capitalization of KALV is $597.08M. In the past 24 hours, 474,630 KALV shares were traded.
How to Buy Kalvista Pharmaceuticals Stock
Wondering how to invest in Kalvista Pharmaceuticals stock? Here's how.
- Decide where to buy Kalvista Pharmaceuticals stock: You need to pick a stock brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you decide where to buy Kalvista Pharmaceuticals stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Deposit funds into your brokerage account: Choose your method of payment and add your information.
- Research Kalvista Pharmaceuticals stock: The Kalvista Pharmaceuticals ticker symbol is KALV. Is Kalvista Pharmaceuticals stock a good investment? Should you buy shares of KALV? How do KALV's underlying business fundamentals look? Do top analysts think Kalvista Pharmaceuticals is a good buy? Why has KALV's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if KALV is a good stock to buy).
- Execute your KALV purchase: Decide if you will purchase KALV shares at the current market price or use a limit order to buy KALV shares at a particular price.
- Track your KALV position: Create a watchlist to important notifications about your new investment in Kalvista Pharmaceuticals stock.
Step 1: Decide where to buy Kalvista Pharmaceuticals stock
You will need an online brokerage account to access the NASDAQ market and buy KALV stock.
Our recommended brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Tech to Energy, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the best brokerage, you need to fill out some personal info so you are able to buy KALV today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal details to start a new trading account.
- Submit your info by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you have created your account on apps for stock market, your next step is to transfer the money for your investment:
Watch the video below if you need help transferring money into your new brokerage account.
Step 4: Research Kalvista Pharmaceuticals stock
Once you have chosen the best place to buy Kalvista Pharmaceuticals stock, it's absolutely critical to analyze their stock prior to investing, so you actually understand the risk as well as the opportunity.
Kalvista Pharmaceuticals Numbers
KALV Due Diligence Score
WallStreetZen was created to help part-time investors perform better fundamental analysis quickly.
You can see all of the due diligence checks on KALV's stock page.
Is KALV stock properly valued?
You can use many financial metrics, analyses, models, and charts to gauge KALV's intrinsic value.
Using relative valuations metrics:
- KALV could be overvalued based on its P/B ratio of 4.11x, relative to Biotechnology industry P/B ratio of 4.04x
You can do additional valuation analysis on KALV's stock here.
KALV Financials at a glance
Pros:
- KALV has cash burn of 128184000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the KALV balance sheet.
- There are more short-term assets than short-term liabilities on the KALV balance sheet.
Cons:
- KALV has $253.20M in cash and short term investments. This is not enough to cover its annual cash burn of $128.18M.
- Total KALV debt is higher than 5 years ago, relative to shareholder equity.
- KALV has a relatively high debt to equity ratio of 0.9.
Is it a good time to buy Kalvista Pharmaceuticals stock, according to analysts?
Out of 6 Wall Street analysts who give forecasts on KALV, the consensus analyst rating on KALV is a Strong Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
Most Recent KALV Analyst Ratings
Tazeen Ahmad, a bottom 8% analyst from Bank of America initiates coverage on KALV with a strong buy rating and announces their KALV price target of $22.00, on Dec 18, 2024.
You can dive deeper into what analysts are saying on the Kalvista Pharmaceuticals stock forecast page.
Metrics for Advanced KALV Traders
How is KALV performing as a company?
Last year, KALV revenue was $0.00. In the last 5 year, KALV's revenue has grown by -100% per year. This was slower than the Biotechnology industry average of 44.31%.
Learn more about KALV's earnings and revenue performance here.
Are KALV executives and large shareholders buying or selling the stock?
In the last year, executives and large shareholders at KALV have bought more shares than they have sold.
Venrock Healthcare Capital Partners III LP, 10% Owner of KALV, was the latest KALV insider to buy. They bought $235,500.00 worth of KALV stock on Apr 9, 2025.
Learn more about who owns KALV stock here.
Can I get consistent income from KALV stock?
No, Kalvista Pharmaceuticals doesn't provide an income stream by paying out dividends.
What do other traders have to say about KALV?
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Execute your KALV purchase
There are two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are generally the easiest way to buy. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at an exact price limit, place a limit order.
Hit the Open button and your broker will place your order.
If you need more info about investing in stocks on eToro, watch the how to video below:
Step 6: Track your KALV position
Now that you own some KALV shares, you'll want to stay up-to-date on your new investment.
Make a watchlist to track the latest developments regarding your KALV stock.
KALV Feed
How to Buy Stock in Kalvista Pharmaceuticals
To summarize, here are the 6 steps for buying Kalvista Pharmaceuticals stock:
- Decide where to buy Kalvista Pharmaceuticals stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Research Kalvista Pharmaceuticals stock
- Execute your KALV purchase
- Track your KALV position
If you need a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to track your investment in Kalvista Pharmaceuticals, create a watchlist today.
Other Articles You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.